Agilent Technologies (NYSE:A) Releases FY23 Earnings Guidance

Agilent Technologies (NYSE:A – Get Rating) issued an update on its FY23 earnings guidance on Tuesday morning. The company provided earnings per share (EPS) guidance of $5.60-5.65 for the period, compared to the consensus estimate of $5.69. The company issued revenue guidance of $6.93-7.03 billion, compared to the consensus revenue estimate of $7.09 billion. Agilent Technologies also updated its Q3 guidance to $1.36-1.38 EPS.

Agilent Technologies Price Performance

A opened at $119.49 on Friday. The business has a fifty day moving average of $133.52 and a 200 day moving average of $143.94. Agilent Technologies has a 52-week low of $112.52 and a 52-week high of $160.26. The company has a quick ratio of 1.53, a current ratio of 2.11 and a debt-to-equity ratio of 0.49. The stock has a market cap of $35.33 billion, a P/E ratio of 26.32, a PEG ratio of 1.89 and a beta of 1.03.

Agilent Technologies (NYSE:A – Get Rating) last posted its quarterly earnings data on Tuesday, May 23rd. The medical research company reported $1.27 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.26 by $0.01. Agilent Technologies had a return on equity of 30.74% and a net margin of 19.19%. The company had revenue of $1.72 billion during the quarter, compared to analysts’ expectations of $1.67 billion. During the same quarter in the previous year, the business earned $1.13 EPS. Agilent Technologies’s revenue was up 6.8% compared to the same quarter last year. As a group, sell-side analysts anticipate that Agilent Technologies will post 5.68 EPS for the current year.

Agilent Technologies Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, July 26th. Shareholders of record on Monday, July 3rd will be given a dividend of $0.225 per share. This represents a $0.90 dividend on an annualized basis and a yield of 0.75%. The ex-dividend date is Friday, June 30th. Agilent Technologies’s dividend payout ratio (DPR) is presently 19.82%.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on A shares. TD Cowen decreased their target price on Agilent Technologies from $168.00 to $145.00 and set an outperform rating for the company in a research report on Wednesday. StockNews.com started coverage on Agilent Technologies in a research report on Thursday, May 18th. They issued a buy rating for the company. Credit Suisse Group reduced their price target on Agilent Technologies from $170.00 to $160.00 and set an outperform rating for the company in a research report on Wednesday. SVB Securities reduced their price target on Agilent Technologies from $170.00 to $145.00 and set an outperform rating for the company in a research report on Wednesday. Finally, Robert W. Baird dropped their target price on Agilent Technologies from $174.00 to $144.00 and set an outperform rating on the stock in a research note on Wednesday. Three investment analysts have rated the stock with a hold rating and twelve have given a buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of Moderate Buy and an average target price of $151.35.

Institutional Trading of Agilent Technologies

Hedge funds and other institutional investors have recently bought and sold shares of the business. Money Concepts Capital Corp acquired a new stake in shares of Agilent Technologies during the fourth quarter worth about $26,000. Ancora Advisors LLC purchased a new stake in Agilent Technologies in the 4th quarter valued at approximately $34,000. Resurgent Financial Advisors LLC purchased a new stake in Agilent Technologies in the 4th quarter valued at approximately $57,000. Altshuler Shaham Ltd boosted its holdings in Agilent Technologies by 94.6% in the 4th quarter. Altshuler Shaham Ltd now owns 395 shares of the medical research company’s stock valued at $59,000 after purchasing an additional 192 shares in the last quarter. Finally, Milestone Investment Advisors LLC purchased a new stake in shares of Agilent Technologies during the 1st quarter worth approximately $61,000. 85.51% of the stock is currently owned by institutional investors and hedge funds.

Agilent Technologies Company Profile

(Get Rating)

Agilent Technologies, Inc engages in the provision of application focused solutions for life sciences, diagnostics, and applied chemical markets. It operates through the following segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers application-focused solutions that include instruments and software that identify, quantify, and analyze the physical and biological properties of substances and products, as well as the clinical and life sciences research areas to interrogate samples at the molecular and cellular level.